An Open-label Study of the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer

Summary

This Phase 2 Open-label Study examines the efficacy, safety, tolerability, and pharmacokinetics (PK) of tomivosertib (eFT508) in Patients with advanced CRPC. An Open-label Study Examining the Effect of tomivosertib (eFT508) in Patients with Advanced Castrate-resistant Prostate Cancer (CRPC)

Timeline

Start

2018-11-27

Primary completion

2020-04-27

Completion

2020-04-27

Outcome

Outcome not reported

Stopped: “Terminated early due to a lack of efficacy.”

Drugs

Indications